Heart pump study tracks Long-Term survival in failing hearts

NCT ID NCT07382284

Recruiting now Knowledge-focused Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 300 adults with end-stage heart failure who receive a left ventricular assist device (LVAD) as part of their routine care. Researchers will track survival, complications, and hospital readmissions over 3-5 years, and analyze heart tissue and blood samples to find biological clues linked to better outcomes. The goal is to learn more about long-term prognosis, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors better predict which patients benefit most from LVADs and improve long-term care strategies.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may take years and might not change current practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

advanced heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END-STAGE HEART FAILURE

Contacts and locations

Locations

+86 025 83106666
RECRUITING

Nanjing, Jiangsu, 210000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.